MedTrace Logo

Registry of Cell Therapy in Non-Ischemic Dilated Cardiomyopathy

NCT02445534 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2024-07-03

No results posted yet for this study

Summary

Although several studies have demonstrated beneficial effects of stem cell therapy in patients with non-ischemic dilated cardiomyopathy, the long term benefits and predictors of response to therapy remain undefined. The aim of this registry is to pool long-term clinical data in patients with non-ischemic dilated cardiomyopathy undergoing autologous cell therapy in an attempt to better define predictors of response to such treatment.

Conditions

  • Cardiomyopathy, Dilated

Interventions

BIOLOGICAL

Autologous stem cell therapy

All patients received granulocyte-colony stimulating factor (G-CSF; 5 mg/kg, 5 days). CD34+ cell were then collected by apheresis and injected transendocardially or intracororonary.

Sponsors & Collaborators

  • University Medical Centre Ljubljana

    lead OTHER

Principal Investigators

  • Bojan Vrtovec, MD, PhD · UMC Ljubljana

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2027-01-31
Completion
2027-05-31

Countries

  • Slovenia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02445534 on ClinicalTrials.gov